Dyne Therapeutics Inc. (NASDAQ:DYN) is one of them 10 Stocks Investors Watch
Dyne Therapeutics saw its shares jump 11.81 percent to close at $19.78 apiece on Tuesday, after the investment firm reiterated its potential triple-digit upside for its stock.
In a market report, Jefferies on Dyne Therapeutics Inc. (NASDAQ:DYN) issued a “Buy” rating with a $50 price target. This number represents a potential upside of 153 percent from its last closing price.
Photo by Pietro Jing on Pixels
Jefferies said the rating reflects his confidence in the rapid approval of this treatment candidate for DM1.
On Monday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced that it will formally initiate a phase 3 trial to study the efficacy of zilikamente bacivarcin in patients with DM1, following a phase 2 study.
Called the HARMONIA trial, the study will enroll 150 participants aged 16 or older, who will be randomized 1:1 to receive 6.8 mg/kg z-basivarsen or placebo every eight weeks (Q8W).
The aim of the study is to measure the improvement in the “sit-to-stand” test five times compared to their starting point, after 49 weeks of treatment.
“HARMONIA is a large, long-term study using a clinically meaningful functional measure as the primary endpoint. HARMONIA is designed to leverage the best-in-class potential of z-basivarsen based on the distinct capabilities of our potency platform to deliver therapeutics to a wide range of musculoskeletal systems,” and CNSDA (CNSDA) Inc. Chief Medical Officer Doug Kerr said.
While we acknowledge DYN’s potential as an investment, our belief is that some AI stocks hold great promise for delivering high returns and limited risk. If you’re looking for a very cheap AI stock that’s also a big beneficiary of Trump’s tariffs and onsuring, check out our free report Best short-term AI stocks.
Read more: 30 stocks that should double in 3 years and 11 Secret AI Stocks to Buy Right Now.
Disclosure: None. Follow the inside port on Google News.
